SABCS 2022 | Trastuzumab deruxtecan in metastatic HER2+ breast cancer

Sibylle Loibl, MD, PhD, German Breast Group, Neu-Isenburg, Germany, discusses the successes of trastuzumab deruxtecan for breast cancer in the HER2-positive metastatic breast cancer setting, such as seen in the Phase III DESTINY-Breast02 (NCT03523585) trial which demonstrated significant delays in disease progression. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.